“Government interventions brings immense opportunities for growth in EPO biosimilar market, says RNCOS research”.
Noida, UP -- (SBWIRE) -- 07/14/2014 -- Due to unprecedented patent expirations and certain financial crisis, government across the world has been pushing the availability of EPO biosimilars at a much discounted rate in the market in a way to reduce the healthcare costs. For Instance, CEO of biotechnology Industry organization has promoted company’s biosimilar bill to provide them access to biologic medicines. Besides, EMA has planned to introduce risk management plans to lead the world in biosimilar regulation. This in turn increases the prescriber’s confidence and also encourages use of biosimilars.
However, in a country like America where there is no regulatory pathway for biosimilar regulation. The whole situation will turn out in 2014 when Patient Protection and Affordable Care Act of 2010 came into force so as to optimize the biosimilar industry development. A remarkable support by government has been provided across the globe to create a biosimilar regulatory platform. Meanwhile, South Korean Pharmaceutical industry has been aiming to implement an aggressive marketing approach targeting the price as key strategy to tap this market. Moreover, across other different nations government has been encouraging the biosimilar regulation development through various partnerships.
As per the estimations of our latest report, “Global EPO Biosimilars Market Outlook 2018”, the global biosimilars market backed by the rise of bioclusters in emerging countries will grow at a CAGR of around 48.3% during 2012-2018. The report contains a thorough study of the EPO biosimilars market, and its future outlook. A basic overview of the total biologics market has been provided, alongwith its current and future size and the trends and drivers which would be responsible for shaping up the market. Some of these factors including rising collaborations among major pharma players and the strong government support to encourage the growth of biosimilars. This is then followed by the total biosimilar market and its future size. The major key segments of the market and their respective shares have also been highlighted.
A brief introduction of the global EPO biosimilar market, its estimated size and its future value has been given. We have also provided a list of the marketed EPO biosimilars and those that are in the pipeline. At the end, key players of the EPO biosimilar market have been profiled where focus has been rested on the business overview, key products and pipeline of the company. Overall, the report aims at providing reliable and complete information about the EPO biosimilar market to clients and potential investors.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM656.htm
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.